User profiles for Amy Rogers
 | Amy RogersClinical Research Fellow, University of Dundee Verified email at dundee.ac.uk Cited by 867 |
[HTML][HTML] Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective …
Background Studies have suggested that evening dosing with antihypertensive therapy
might have better outcomes than morning dosing. The Treatment in Morning versus Evening (…
might have better outcomes than morning dosing. The Treatment in Morning versus Evening (…
[HTML][HTML] Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint …
…, I Ford, N Greenlaw, F Pigazzani, A Rogers… - The Lancet, 2022 - thelancet.com
Background Allopurinol is a urate-lowering therapy used to treat patients with gout.
Previous studies have shown that allopurinol has positive effects on several cardiovascular …
Previous studies have shown that allopurinol has positive effects on several cardiovascular …
Evaluation of transport media and specimen transport conditions for the detection of SARS-CoV-2 by use of real-time reverse transcription-PCR
AA Rogers, RE Baumann, GA Borillo… - Journal of clinical …, 2020 - Am Soc Microbiol
The global coronavirus (CoV) disease 2019 (COVID-19) pandemic has resulted in a
worldwide shortage of viral transport media and raised questions about specimen stability. The …
worldwide shortage of viral transport media and raised questions about specimen stability. The …
Toward precision medicine: circadian rhythm of blood pressure and chronotherapy for hypertension-2021 NHLBI workshop report
Healthy individuals exhibit blood pressure variation over a 24-hour period with higher blood
pressure during wakefulness and lower blood pressure during sleep. Loss or disruption of …
pressure during wakefulness and lower blood pressure during sleep. Loss or disruption of …
[HTML][HTML] Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma
…, L Admojo, AJ Davenport, K Richardson, A Rogers… - Scientific reports, 2018 - nature.com
Mucosal-associated invariant T (MAIT) cells are T cells that recognise vitamin-B derivative
Ag presented by the MHC-related-protein 1 (MR1) antigen-presenting molecule. While MAIT …
Ag presented by the MHC-related-protein 1 (MR1) antigen-presenting molecule. While MAIT …
The buccal flap—a useful technique in cleft palate repair?
…, AA Moreira-Gonzalez, A Rogers… - The Cleft palate …, 2004 - journals.sagepub.com
Objective To evaluate speech quality and oronasal fistula after primary palate repair using a
buccal mucosal flap. Design Retrospective study cohort of patients with cleft palate. Setting …
buccal mucosal flap. Design Retrospective study cohort of patients with cleft palate. Setting …
Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In …
Introduction Nocturnal blood pressure (BP) appears to be a better predictor of cardiovascular
outcome than daytime BP. The BP lowering effects of most antihypertensive therapies are …
outcome than daytime BP. The BP lowering effects of most antihypertensive therapies are …
[HTML][HTML] Telehealth personalized cancer risk communication to motivate colonoscopy in relatives of patients with colorectal cancer: the family CARE randomized …
…, MD Schwartz, SL Edwards, A Rogers… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
Purpose The rate of adherence to regular colonoscopy screening in individuals at increased
familial risk of colorectal cancer (CRC) is suboptimal, especially among rural and other …
familial risk of colorectal cancer (CRC) is suboptimal, especially among rural and other …
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
ZA Wainberg, A Anghel, AM Rogers, AJ Desai… - Molecular cancer …, 2013 - AACR
HSP90 enables the activation of many client proteins of which the most clinically validated
is HER2. NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clinical trials. To …
is HER2. NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clinical trials. To …
[HTML][HTML] Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis
The BCL6 Corepressor (BCOR) is a component of a variant Polycomb repressive complex 1
(PRC1) that is essential for normal development. Recurrent mutations in the BCOR gene …
(PRC1) that is essential for normal development. Recurrent mutations in the BCOR gene …